Loading stock data…
COGT
$36.63+0.84 (+2.35%)
Market ClosedLast close May 1
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cogent Biosciences, Inc. in the Healthcare sector is trading at $36.63. The stock is currently near its 52-week high of $43.73, remaining 33.2% above its 200-day moving average. Technical signals show neutral RSI of 51 and bearish MACD signal, explaining why COGT maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$36.63
Potential Upside
5%
Whystock Fair Value$38.46
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$54.17+47.9%
Range$35.00 – $72.00
Fundamentals
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.86B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.47
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-19.73%
Volume
Today's trading volume
1.93M
Recent News
Does Bezuclastinib’s Real-Time FDA Review and NDA Filing Change The Bull Case For Cogent Biosciences (COGT)?
Cogent Biosciences recently completed and submitted its New Drug Application to the FDA for bezuclastinib in previously treated GIST patients, supported by Phase 3 PEAK data showing materially longer progression-free survival and higher response rates versus sunitinib alone, and inclusion in the FDA’s Real-Time Oncology Review program. Alongside Breakthrough Therapy Designation, active expanded access programs, and plans for additional GIST and AdvSM trials, growing interest from...
Southwest Airlines, Colliers International, and More Stocks See Action From Activist Investors
Activists also report to the SEC on MoonLake Immunotherapeutics, BridgeBio Pharma, Southwest Airlines, and Cogent Biosciences.
Cogent Biosciences (COGT): Billionaire Stan Druckenmiller Admires Upside Potential of This Stock
Cogent Biosciences, Inc. (NASDAQ:COGT) is one of Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge Upside Potential. Cogent Biosciences, Inc. (NASDAQ:COGT) is a relatively recent addition to the 13F portfolio of Duquesne Capital. The fund first disclosed a stake in the company in the third quarter of 2025. This position comprised just […]
Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts
UBS analysts have outlined a set of high-conviction healthcare ideas where they believed the market was underappreciating earnings durability and the scale of upcoming catalysts, focusing on stocks backed by differentiated views and proprietary insights. In biotechnology, they identified...
A Look At Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Shifting Institutional Positions
The key catalyst for Cogent Biosciences (COGT) is the FDA’s acceptance of its New Drug Application for bezuclastinib in NonAdvanced Systemic Mastocytosis, with a PDUFA target action date set for December 30, 2026. See our latest analysis for Cogent Biosciences. The share price recently closed at $35.41, with a 6.08% 1 day share price return following the FDA’s NDA acceptance and mixed institutional trading. The 1 year total shareholder return of very large magnitude indicates strong longer...